Anti-AgingPreclinicalAnimal Studies

Vesilute

Also known as ED Dipeptide, Glu-Asp, L-Glutamyl-L-Aspartic Acid

A synthetic dipeptide (Glu-Asp) bioregulator from the Khavinson peptide family, studied for urinary tract and prostate support.

Preclinical - Limited human studies, available as supplement in some regions

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

1-2 capsules (10-20 mg) daily

Frequency

1-2x daily, before meals

Duration

30-day courses, repeat after 4-6 months

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 1-2 capsules (10-20 mg) daily via Oral capsules, 1-2x daily, before meals. Dose range: 10-20 mg daily. Duration: 30-day courses, repeat after 4-6 months.

Timing & Administration

Administer via Oral capsules. Frequency: 1-2x daily, before meals.

Mechanism of Action

Normalizes cellular function by reducing peptide deficiency and restoring protein synthesis inside cells. May enhance microcirculation within the prostate and support bladder function through epigenetic regulation.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical - Limited human studies, available as supplement in some regions.

Side Effects & Safety

Important Warnings

  • Limited published peer-reviewed research
  • Limited Western safety data.
Generally well-tolerated
individual intolerance possible
unknown long-term effects

References

No references available.